Clinical Trial Update: ELBA: Exemestane and Lapatinib in Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial (ELBA) evaluating exemestane and lapatinib for advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Tykerb (lapatinib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN